Next Article in Journal
Assessing Tumor Response to Treatment in Patients with Lung Cancer Using Dynamic Contrast-Enhanced CT
Next Article in Special Issue
A Promising Future for Prostate Cancer Diagnostics
Previous Article in Journal
Mobile Diagnostics Based on Motion? A Close Look at Motility Patterns in the Schistosome Life Cycle
Previous Article in Special Issue
Limitations and Prospects for Diffusion-Weighted MRI of the Prostate
Article Menu

Export Article

Open AccessReview
Diagnostics 2016, 6(3), 27; doi:10.3390/diagnostics6030027

The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer

1
UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
2
School of Medicine, Trinity College Dublin, Dublin 2, Ireland
3
St. Luke’s Hospital, Rathgar, Dublin 6, Ireland
*
Authors to whom correspondence should be addressed.
Academic Editor: Stephen Assinder
Received: 6 April 2016 / Revised: 28 June 2016 / Accepted: 7 July 2016 / Published: 18 July 2016
(This article belongs to the Special Issue Prostate Cancer Diagnosis)
View Full-Text   |   Download PDF [3524 KB, uploaded 19 July 2016]   |  

Abstract

Prostate Cancer (PCa) is the second most commonly diagnosed cancer in men worldwide. Although increased expression of prostate-specific antigen (PSA) is an effective indicator for the recurrence of PCa, its intended use as a screening marker for PCa is of considerable controversy. Recent research efforts in the field of PCa biomarkers have focused on the identification of tissue and fluid-based biomarkers that would be better able to stratify those individuals diagnosed with PCa who (i) might best receive no treatment (active surveillance of the disease); (ii) would benefit from existing treatments; or (iii) those who are likely to succumb to disease recurrence and/or have aggressive disease. The growing demand for better prostate cancer biomarkers has coincided with the development of improved discovery and evaluation technologies for multiplexed measurement of proteins in bio-fluids and tissues. This review aims to (i) provide an overview of these technologies as well as describe some of the candidate PCa protein biomarkers that have been discovered using them; (ii) address some of the general limitations in the clinical evaluation and validation of protein biomarkers; and (iii) make recommendations for strategies that could be adopted to improve the successful development of protein biomarkers to deliver improvements in personalized PCa patient decision making. View Full-Text
Keywords: prostate cancer; proteomics; biomarkers; multiple reaction monitoring; clinical validation prostate cancer; proteomics; biomarkers; multiple reaction monitoring; clinical validation
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Tonry, C.L.; Leacy, E.; Raso, C.; Finn, S.P.; Armstrong, J.; Pennington, S.R. The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer. Diagnostics 2016, 6, 27.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top